Helena Lizana1, Lennart Johansson2, Jan Axelsson2, Anne Larsson2, Mattias Ögren3, Jan Linder4, Christer Halldin5, Andrea Varrone5, Susanna Jakobson Mo3. 1. Radiation Physics, Department of Radiation Sciences, Umeå University, Umeå, Sweden helena.lizana@vll.se. 2. Radiation Physics, Department of Radiation Sciences, Umeå University, Umeå, Sweden. 3. Diagnostic Radiology, Department of Radiation Sciences, Umeå University, Umeå, Sweden. 4. Clinical Neuroscience, Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden; and. 5. Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Abstract
18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4'-methyl-phenyl) nortropane (18F-FE-PE2I) was recently developed and has shown adequate affinity and high selectivity for the dopamine transporter (DAT). Previous studies have shown promising results for 18F-FE-PE2I as a suitable radioligand for DAT imaging. In this study, we investigated the whole-body biodistribution and dosimetry of 18F-FE-PE2I in healthy volunteers to support its utility as a suitable PET imaging agent for the DAT. Methods: Five healthy volunteers were given a mean activity of 2.5 MBq/kg, and 3 PET scans, head to thigh, were performed immediately after injection followed by 4 whole-body PET/CT scans between 0.5 and 6 h after injection. Blood samples were drawn in connection with the whole-body scans, and all urine was collected until 6 h after injection. Volumes of interest were delineated around 17 organs on all images, and the areas under the time-activity curves were calculated to obtain the total number of decays in the organs. The absorbed doses to organs and the effective dose were calculated using the software IDAC. Results: The highest activity concentration was observed in the liver (0.9%-1.2% injected activity/100 g) up to 30 min after injection. At later time points, the highest concentration was seen in the gallbladder (1.1%-0.1% injected activity/100 g). The activity excreted with urine ranged between 23% and 34%, with a mean of 28%. The urinary bladder received the highest absorbed dose (119 μGy/MBq), followed by the liver (46 μGy/MBq). The effective dose was 23 μSv/MBq (range, 19-28 μSv/MBq), resulting in an effective dose of 4.6 mSv for an administered activity of 200 MBq. Conclusion: The effective dose is within the same order of magnitude as other commonly used PET imaging agents as well as DAT agents. The reasonable effective dose, together with the previously reported favorable characteristics for DAT imaging and quantification, indicates that 18F-FE-PE2I is a suitable radioligand for DAT imaging.
18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4'-methyl-phenyl) nortropane (18F-FE-PE2I) was recently developed and has shown adequate affinity and high selectivity for the dopamine transporter (DAT). Previous studies have shown promising results for 18F-FE-PE2I as a suitable radioligand for DAT imaging. In this study, we investigated the whole-body biodistribution and dosimetry of 18F-FE-PE2I in healthy volunteers to support its utility as a suitable PET imaging agent for the DAT. Methods: Five healthy volunteers were given a mean activity of 2.5 MBq/kg, and 3 PET scans, head to thigh, were performed immediately after injection followed by 4 whole-body PET/CT scans between 0.5 and 6 h after injection. Blood samples were drawn in connection with the whole-body scans, and all urine was collected until 6 h after injection. Volumes of interest were delineated around 17 organs on all images, and the areas under the time-activity curves were calculated to obtain the total number of decays in the organs. The absorbed doses to organs and the effective dose were calculated using the software IDAC. Results: The highest activity concentration was observed in the liver (0.9%-1.2% injected activity/100 g) up to 30 min after injection. At later time points, the highest concentration was seen in the gallbladder (1.1%-0.1% injected activity/100 g). The activity excreted with urine ranged between 23% and 34%, with a mean of 28%. The urinary bladder received the highest absorbed dose (119 μGy/MBq), followed by the liver (46 μGy/MBq). The effective dose was 23 μSv/MBq (range, 19-28 μSv/MBq), resulting in an effective dose of 4.6 mSv for an administered activity of 200 MBq. Conclusion: The effective dose is within the same order of magnitude as other commonly used PET imaging agents as well as DAT agents. The reasonable effective dose, together with the previously reported favorable characteristics for DAT imaging and quantification, indicates that 18F-FE-PE2I is a suitable radioligand for DAT imaging.
Authors: Silvia Morbelli; Giuseppe Esposito; Javier Arbizu; Henryk Barthel; Ronald Boellaard; Nico I Bohnen; David J Brooks; Jacques Darcourt; John C Dickson; David Douglas; Alexander Drzezga; Jacob Dubroff; Ozgul Ekmekcioglu; Valentina Garibotto; Peter Herscovitch; Phillip Kuo; Adriaan Lammertsma; Sabina Pappata; Iván Peñuelas; John Seibyl; Franck Semah; Livia Tossici-Bolt; Elsmarieke Van de Giessen; Koen Van Laere; Andrea Varrone; Michele Wanner; George Zubal; Ian Law Journal: Eur J Nucl Med Mol Imaging Date: 2020-05-09 Impact factor: 9.236
Authors: Lisbeth Marner; Kirsten Korsholm; Lasse Anderberg; Markus N Lonsdale; Mads Radmer Jensen; Eva Brødsgaard; Charlotte L Denholt; Nic Gillings; Ian Law; Lars Friberg Journal: EJNMMI Res Date: 2022-09-07 Impact factor: 3.434
Authors: Susanna Jakobson Mo; Jan Axelsson; Lars Jonasson; Anne Larsson; Mattias J Ögren; Margareta Ögren; Andrea Varrone; Linda Eriksson; David Bäckström; Sara Af Bjerkén; Jan Linder; Katrine Riklund Journal: EJNMMI Res Date: 2018-11-15 Impact factor: 3.138